Roupen Odabashian discussing the current state of AI scribes and Heidi Health with Thomas Kelly
Roupen Odabashian shared a post on LinkedIn by Delta: HealthTech Innovators, adding:
“I Had a fantastic time meeting Dr. Thomas Kelly to discuss the current state of AI scribes and Heidi Health.
We delved into how physicians can break into innovation and the valuable lessons Dr. Kelly learned transitioning from medicine to entrepreneurship.
For the full episode, tune into our Delta: HealthTech Innovators podcast.”
Quoting Delta: HealthTech Innovators‘ post:
“This was a great episode with Dr. Kelly!
Together, we discussed the future of AI scribes, customization in healthcare, and the challenges of building innovative medical tools.
For the full episode, check out our YouTube video.
Sources: Roupen Odabashian/LinkedIn and Delta: HealthTech Innovators/LinkedIn
More posts by Roupen Odabashian on oncodaily.com
Roupen Odabashian is an accomplished Internal Medicine Physician and Hematology/Oncology Fellow committed to advancing healthcare through clinical practice, research, and technology.
Currently based at the Karmanos Cancer Institute, Dr. Odabashian is actively involved in pioneering cancer treatments and conducting clinical research. He hosts a podcast at OncoDaily and contributes his expertise as an advisor at Spiraldot Health and Mesh AI.
Thomas Kelly is the Co-Founder and CEO of Heidi Health, a Limited Partner at Blackbird, and a Board Member at Fraser’s GAMSAT. He previously worked as a Surgical Registrar at Alfred Health.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023